3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
9
Lymphoma
3
Carcinoma, Hepatocellular
3
Cardiotoxicity
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Fatigue
1
Fallopian Tube Neoplasms
1
Desmoid Tumors
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Cancer Organoids
1
Brain Neoplasms
1
Interventions
Blood Specimen Collection
6
Liquid Biopsy
3
Chemotherapy, Adjuvant
2
trastuzumab deruxtecan
1
pegaspargase
1
Vincristine
1
Trastuzumab
1
Transplantation, Autologous
1
Prednisone
1
Neoadjuvant Therapy
1
Methotrexate
1
Mercaptopurine
1
Hematologic Tests
1
Drug Therapy
1
Doxorubicin
1
Daunorubicin
1
Cytoreduction Surgical Procedures
1
Cytarabine
1
Cyclophosphamide
1
Clonal Evolution
1
Anti-Inflammatory Agents, Non-Steroidal
1
Aminolevulinic Acid
1
Ado-Trastuzumab Emtansine
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasm, Residual
×
Doxorubicin
×
Clear all
NCT05959720
2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
180 enrolled